MRDAC: A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD)(in collaboration with Novartis Pharma GmbH, Nürnberg)

A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD).

Ansprechpartner: Dr. Martin Büchert
Tel: 0761-270-7411
Email: martin.buechert@uniklinik-freiburg.de

Projektbeginn: 01.10.2006
Projektende: 30.09.2009

Hennig J, Büchert M, Walz G

Albert-Ludwigs-Universität Freiburg
Department für Radiologische Diagnostik und Therapie
Klinik für Radiologie
Hugstetterstrasse 55
79106 Freiburg

Telefon: +49-761-270-38050/38060
Fax: +49-761-270-38380

• Novartis Pharma GmbH, Firma